Showing results (181-190 of 202) with videos related to

Sort By:
Pageof 21
Leukemia & Lymphoma|October 31, 2006
Down-regulation of cellular vascular endothelial growth factor levels induces differentiation of leukemic cells to functional leukemic-dendritic cells in acute myeloid leukemiaHyun-Kyu Kang, Jung-Sun Park, Sang-Ki Kim, et al.
Journal of Clinical Apheresis|November 23, 2006
Optimization of the concentration of autologous serum for generation of leukemic dendritic cells from acute myeloid leukemic cells for clinical immunotherapyBo-Hwa Choi, Hyun-Kyu Kang, Jung-Sun Park, et al.
International Journal of Radiation Oncology, Biology, Physics|November 19, 2023
Direct Tumor Irradiation Potentiates Adoptive NK Cell Targeting Against Parental and Stemlike Cancer in Human Liver Cancer ModelsTung Nguyen Thanh Uong, Meesun Yoon, Ik-Joo Chung, et al.
Annals of Laboratory Medicine|December 25, 2023
Current Status of Flow Cytometric Immunophenotyping of Hematolymphoid Neoplasms in KoreaMikyoung Park, Jihyang Lim, Ari Ahn, et al.
Cancer Research and Treatment|July 3, 2025
A Phase II Study of Daratumumab in Combination with Bortezomib and Dexamethasone in Patients with Multiple Myeloma Who Received One Prior Line of Therapy (KMM1906)Kwai Han Yoo, Sang Eun Yoon, Ka-Won Kang, et al.
Journal of Clinical Medicine|January 18, 2020
Phase I Study of a B Cell-Based and Monocyte-Based Immunotherapeutic Vaccine, BVAC-C in Human Papillomavirus Type 16- or 18-Positive Recurrent Cervical CancerChel Hun Choi, Hyun Jin Choi, Jeong-Won Lee, et al.
Cancer Immunology, Immunotherapy : CII|November 17, 2022
Expanded natural killer cells potentiate the antimyeloma activity of daratumumab, lenalidomide, and dexamethasone in a myeloma xenograft modelJaya Lakshmi Thangaraj, Sung-Hoon Jung, Manh-Cuong Vo, et al.
Cellular & Molecular Immunology|May 13, 2021
Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse modelJaya Lakshmi Thangaraj, Seo-Yeon Ahn, Sung-Hoon Jung, et al.
Blood Advances|December 9, 2025
Microbiome and metabolite biomarkers of CAR T-cell therapy outcomes in relapsed/refractory diffuse large B cell lymphomaSang Eun Yoon, Woorim Kang, Junhun Cho, et al.
Blood|August 9, 2020
Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 studySeok Jin Kim, Jing Quan Lim, Yurike Laurensia, et al.
Pageof 21